Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
M. Jakopovic, B. Cucevic, S. Plestina, S. Smojver-Jezek, S. Kukulj, N. Chalfe, M. Korsic, Z. Vrbica, G. Redzepi, M. Samarzija (Zagreb, Dubrovnik, Croatia). Safety and efficacy of erlotinib in patients with squamous cell lung cancer. Eur Respir J 2014; 44: Suppl. 58, 2722

Member's Comments

No comment yet.

Related content which might interest you: ALK/EML4 translocation in non-squamous NSCLC and their predictors Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Progression vs. pseudo progression in the treatment of squamous NSCLC with nivolumab Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Treatment of advanced non-small cell lung cancer with trofosfamide Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013 Surgical treatment outcomes on early-stages of non-small-cell lung cancer Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Maintenance therapy with pemetrexed in non-small-cell lung cancer: Impact on survival Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Improving survival for NSCLC patients in the national lung cancer audit Source: International Congress 2015 – Quality management in lung cancer Year: 2015 Algorithm of preoperative N-staging of non-small cell lung cancer Source: Annual Congress 2013 –Oncological thoracic surgery Year: 2013 Symptom-to-treatment intervals in lung cancer Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Methilation status in EBUS-NA samples of lung cancer Source: International Congress 2014 – Improving diagnosis of thoracic tumours Year: 2014 Prognostic factors for survival in lung cancer Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Second primary lung cancer in squamous NSCLC patients: The Nancy Biobank's database Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 Electrospray-mediated local chemotherapy of lung carcinoma in mice Source: International Congress 2016 – Basic science and case reports in lung cancer Year: 2016 Brain metastatic recurrence following radically treated lung cancer; a retrospective analysis Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 EBUS-TBNA for nodal restaging and relapse in lung cancer Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours Year: 2014 Comorbitities, responses and survival in pts with NSCLC Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Functional impairment of NK cells in non-small-cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 The prognostic value of the tumor shrinkage rate for progression-free survival in patients with non-small cell lung cancer receiving gefitinib Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014 Chemotherapy beyond 3rd line in NSCLC – A retrospective analysis Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Predictors of lung cancer patients delay time in Serbia - a cross-sectional study Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014